<DOC>
	<DOCNO>NCT00746772</DOCNO>
	<brief_summary>Oral lichen planus ( OLP ) chronic inflammatory disease whose prevalence general population 0.5 -2.2 % .Oral lesion OLP chronic , rarely undergo spontaneous remission . Patients OLP significantly increase risk oral squamous cell carcinoma , irrespective clinical type OLP therapy . currently cure OLP . Previous study demonstrate decreased antioxidant defence increase oxidative damage lipids.DNA proteins lichen planus . This oxidative modification point pathophysiological alteration mainly within basal cell layer epidermis dermoepidermal junction . Purslane excellent source vitamin A , C E essential amino acid , describe power food future high nutritive antioxidant property . The purpose study determine efficacy Purslane treatment oral lichen planus .</brief_summary>
	<brief_title>Efficacy Purslane Treatment Oral Lichen Planus</brief_title>
	<detailed_description>Oral lichen planus chronic common inflammatory disorder affect stratify squamous epithelium . The majority problem OLP development oral squamous cell carcinoma , irrespective clinical type OLP therapy . Previous study demonstrate decreased antioxidant defence increase oxidative damage lipid , DNA proteins lichen planus .This oxidative modification point pathophysiological alteration mainly within basal cell layer epidermis dermoepidermal junction . So oxidative stress could effective pathogenesis OLP . Purslane excellent source vitamin A , C E essential amino acid , describe power food future high nutritive antioxidant property . Purslane also decrease level TNF-Î± IL6 , responsible up-regulated adhesion molecule ( OLP lymphocyte T ( T cell ) recruit retained sub mucosa receptor endothelial adhesion molecule . basal keratinocytes undergo apoptosis ) . The purpose study determine efficacy Purslane treatment oral lichen planus .</detailed_description>
	<mesh_term>Lichen Planus , Oral</mesh_term>
	<mesh_term>Lichen Planus</mesh_term>
	<mesh_term>Antioxidants</mesh_term>
	<criteria>Biopsy confirm symptomatic oral lichen planus : WHO histological criterion combination clinical appearance use diagnosis Patients symptom burn sensation , pain Patients immunosuppressive immunomodulatory treatment . In case , treatment stop washout period 1 month give . Patients sex 30 70 year 's old Patients give write informed consent Patients willing evaluation second week therapy every 1 month 6 month The presence histological sign dysplasia Patients suffer localize systemic disease Renal disease patient Pregnant patient Patients continue study private social reason Patients use lichenoid reaction include drug</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>antioxidant</keyword>
	<keyword>oral lichen planus</keyword>
	<keyword>treatment</keyword>
	<keyword>purslane</keyword>
</DOC>